Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma

Nicholas E. Papadopoulos, Agop Bedikian, Sigrid Ring, Kevin B. Kim, Wen Jen Hwu, Donna L. Gerber, Jade Homsi, Patrick Hwu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECTIVE:: This phase I/II study was done to evaluate the safety and efficacy of a cisplatin-paclitaxel-dacarbazine regimen in patients with metastatic melanoma. PATIENTS AND METHODS:: Chemotherapy-naive patients with surgically unresectable stage III/IV melanoma who had measurable lesions, no brain metastasis, and an Eastern Oncology Cooperative Group performance status of 0 or 1 were enrolled. Cohorts of 4 patients were treated at each dose level. The starting doses of the drugs were as follows: cisplatin 20 mg/m IV on days 1 to 4, paclitaxel 100 mg/m IV on days 1 and 8, and dacarbazine 800 mg/m IV on day 1 only. The doses of cisplatin and paclitaxel were escalated to the next dose level, until the maximum tolerable doses were reached. The dose level without dose-limiting grade 4 toxicity was chosen for phase II part of the study. The primary end point of the phase II study was to determine the antitumor activity in terms of response rate and survival of patients. RESULTS:: The optimum chemotherapy doses for phase II study were as follows: cisplatin 20 mg/m on days 1 to 4, paclitaxel 120 mg/m on days 1 and 8, and dacarbazine 800 mg/m on day 1. Overall, 46 patients were enrolled in the study. Two complete and 17 partial responses were seen for an overall response rate of 41%. The median overall survival time and time to tumor progression were 11.0 and 4.3 months, respectively. Median response duration was 6.2 months. Myelosuppression and neuropathy were the dose-limiting toxicities. CONCLUSION:: Cisplatin-paclitaxel- dacarbazine regimen is effective in patients with advanced melanoma.

Original languageEnglish (US)
Pages (from-to)509-514
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume32
Issue number5
DOIs
StatePublished - Oct 1 2009

Fingerprint

Dacarbazine
Paclitaxel
Cisplatin
Melanoma
Drug Therapy
Survival Rate
Neoplasm Metastasis
Safety
Survival
Brain
Pharmaceutical Preparations
TP protocol
Neoplasms

Keywords

  • Chemotherapy
  • Melanoma
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Papadopoulos, N. E., Bedikian, A., Ring, S., Kim, K. B., Hwu, W. J., Gerber, D. L., ... Hwu, P. (2009). Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 32(5), 509-514. https://doi.org/10.1097/COC.0b013e3181942a1f

Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. / Papadopoulos, Nicholas E.; Bedikian, Agop; Ring, Sigrid; Kim, Kevin B.; Hwu, Wen Jen; Gerber, Donna L.; Homsi, Jade; Hwu, Patrick.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 32, No. 5, 01.10.2009, p. 509-514.

Research output: Contribution to journalArticle

Papadopoulos, Nicholas E. ; Bedikian, Agop ; Ring, Sigrid ; Kim, Kevin B. ; Hwu, Wen Jen ; Gerber, Donna L. ; Homsi, Jade ; Hwu, Patrick. / Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2009 ; Vol. 32, No. 5. pp. 509-514.
@article{a0922e1401484ccbaafc51a755890042,
title = "Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma",
abstract = "OBJECTIVE:: This phase I/II study was done to evaluate the safety and efficacy of a cisplatin-paclitaxel-dacarbazine regimen in patients with metastatic melanoma. PATIENTS AND METHODS:: Chemotherapy-naive patients with surgically unresectable stage III/IV melanoma who had measurable lesions, no brain metastasis, and an Eastern Oncology Cooperative Group performance status of 0 or 1 were enrolled. Cohorts of 4 patients were treated at each dose level. The starting doses of the drugs were as follows: cisplatin 20 mg/m IV on days 1 to 4, paclitaxel 100 mg/m IV on days 1 and 8, and dacarbazine 800 mg/m IV on day 1 only. The doses of cisplatin and paclitaxel were escalated to the next dose level, until the maximum tolerable doses were reached. The dose level without dose-limiting grade 4 toxicity was chosen for phase II part of the study. The primary end point of the phase II study was to determine the antitumor activity in terms of response rate and survival of patients. RESULTS:: The optimum chemotherapy doses for phase II study were as follows: cisplatin 20 mg/m on days 1 to 4, paclitaxel 120 mg/m on days 1 and 8, and dacarbazine 800 mg/m on day 1. Overall, 46 patients were enrolled in the study. Two complete and 17 partial responses were seen for an overall response rate of 41{\%}. The median overall survival time and time to tumor progression were 11.0 and 4.3 months, respectively. Median response duration was 6.2 months. Myelosuppression and neuropathy were the dose-limiting toxicities. CONCLUSION:: Cisplatin-paclitaxel- dacarbazine regimen is effective in patients with advanced melanoma.",
keywords = "Chemotherapy, Melanoma, Paclitaxel",
author = "Papadopoulos, {Nicholas E.} and Agop Bedikian and Sigrid Ring and Kim, {Kevin B.} and Hwu, {Wen Jen} and Gerber, {Donna L.} and Jade Homsi and Patrick Hwu",
year = "2009",
month = "10",
day = "1",
doi = "10.1097/COC.0b013e3181942a1f",
language = "English (US)",
volume = "32",
pages = "509--514",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma

AU - Papadopoulos, Nicholas E.

AU - Bedikian, Agop

AU - Ring, Sigrid

AU - Kim, Kevin B.

AU - Hwu, Wen Jen

AU - Gerber, Donna L.

AU - Homsi, Jade

AU - Hwu, Patrick

PY - 2009/10/1

Y1 - 2009/10/1

N2 - OBJECTIVE:: This phase I/II study was done to evaluate the safety and efficacy of a cisplatin-paclitaxel-dacarbazine regimen in patients with metastatic melanoma. PATIENTS AND METHODS:: Chemotherapy-naive patients with surgically unresectable stage III/IV melanoma who had measurable lesions, no brain metastasis, and an Eastern Oncology Cooperative Group performance status of 0 or 1 were enrolled. Cohorts of 4 patients were treated at each dose level. The starting doses of the drugs were as follows: cisplatin 20 mg/m IV on days 1 to 4, paclitaxel 100 mg/m IV on days 1 and 8, and dacarbazine 800 mg/m IV on day 1 only. The doses of cisplatin and paclitaxel were escalated to the next dose level, until the maximum tolerable doses were reached. The dose level without dose-limiting grade 4 toxicity was chosen for phase II part of the study. The primary end point of the phase II study was to determine the antitumor activity in terms of response rate and survival of patients. RESULTS:: The optimum chemotherapy doses for phase II study were as follows: cisplatin 20 mg/m on days 1 to 4, paclitaxel 120 mg/m on days 1 and 8, and dacarbazine 800 mg/m on day 1. Overall, 46 patients were enrolled in the study. Two complete and 17 partial responses were seen for an overall response rate of 41%. The median overall survival time and time to tumor progression were 11.0 and 4.3 months, respectively. Median response duration was 6.2 months. Myelosuppression and neuropathy were the dose-limiting toxicities. CONCLUSION:: Cisplatin-paclitaxel- dacarbazine regimen is effective in patients with advanced melanoma.

AB - OBJECTIVE:: This phase I/II study was done to evaluate the safety and efficacy of a cisplatin-paclitaxel-dacarbazine regimen in patients with metastatic melanoma. PATIENTS AND METHODS:: Chemotherapy-naive patients with surgically unresectable stage III/IV melanoma who had measurable lesions, no brain metastasis, and an Eastern Oncology Cooperative Group performance status of 0 or 1 were enrolled. Cohorts of 4 patients were treated at each dose level. The starting doses of the drugs were as follows: cisplatin 20 mg/m IV on days 1 to 4, paclitaxel 100 mg/m IV on days 1 and 8, and dacarbazine 800 mg/m IV on day 1 only. The doses of cisplatin and paclitaxel were escalated to the next dose level, until the maximum tolerable doses were reached. The dose level without dose-limiting grade 4 toxicity was chosen for phase II part of the study. The primary end point of the phase II study was to determine the antitumor activity in terms of response rate and survival of patients. RESULTS:: The optimum chemotherapy doses for phase II study were as follows: cisplatin 20 mg/m on days 1 to 4, paclitaxel 120 mg/m on days 1 and 8, and dacarbazine 800 mg/m on day 1. Overall, 46 patients were enrolled in the study. Two complete and 17 partial responses were seen for an overall response rate of 41%. The median overall survival time and time to tumor progression were 11.0 and 4.3 months, respectively. Median response duration was 6.2 months. Myelosuppression and neuropathy were the dose-limiting toxicities. CONCLUSION:: Cisplatin-paclitaxel- dacarbazine regimen is effective in patients with advanced melanoma.

KW - Chemotherapy

KW - Melanoma

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=70350662205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350662205&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181942a1f

DO - 10.1097/COC.0b013e3181942a1f

M3 - Article

VL - 32

SP - 509

EP - 514

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -